Filter by
Filter by
Breast, The Value of Protons, Cardiotoxicity and RadComp
During ISOP 2022, Shannon McDonald presented "Breast, The Value of Protons, Cardiotoxicity and RadComp".
Watch the webinar above.
Breast and chest wall treatment with pencil beam scanning at the proton therapy center in Prague
The Proton Therapy Centre in Prague (PTC) is a leading global health care facility and one of the most advanced proton therapy providers in Europe. The centre...
Outcomes and toxicities after proton partial breast radiotherapy for early stage, hormone receptor positive breast cancer: 3-Year results of a phase II multi-center trial.
This study reports 3-year outcomes of the Proton Collaborative Group phase II trial (PCG BRE007-12) that recruited women ≥ 50 years with node-negative, estrogen...
Early Toxicity and Patient-Reported Cosmetic Outcomes in Patients Treated With Adjuvant Proton-Based Radiotherapy After Breast-Conserving Surgery.
This study reported early toxicity and cosmetic outcomes of 21 patients treated with breast-conserving surgery and adjuvant PBT. Grade 2 and 3 dermatitis...
CNS & Leptomeningeal Disease
Minesh Mehta covers three indications that are very promising for proton therapy: leptomeningeal disease, low-grade glioma, and glioblastoma. Watch the talk's...
Proton Therapy for Locally Advanced Breast Cancer with a Focus on Cardiac Benefits
Shannon MacDonald covers one of proton therapy's growing indications: breast cancer. In her talk, she focuses on locally advanced breast cancer and cardiac...
DynamicARC: the Future of Proton Therapy
DynamicARC® proton therapy is one of the most promising developments in proton radiation therapy, as it allows dynamic irradiation while the gantry is rotating...
Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial.
Published in the Lancet Oncology, this randomized phase 2 study by the Mayo group was set to compare conventional fractionated (50 Gy in 25 fractions of 2 Gy)...